Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:1640-1646
Published online before print June 12, 2008, doi: 10.1161/ATVBAHA.108.162511
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
28/9/1640    most recent
ATVBAHA.108.162511v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Armstrong, L.-J.
Right arrow Articles by Bicknell, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Armstrong, L.-J.
Right arrow Articles by Bicknell, R.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:1640.)
© 2008 American Heart Association, Inc.


Cell Biology/Signaling

ECSM2, An Endothelial Specific Filamin A Binding Protein That Mediates Chemotaxis

Laura-Jane Armstrong; Victoria L. Heath; Sharon Sanderson; Sukhbir Kaur; James F.J. Beesley; John M.J. Herbert; John A. Legg; Richard Poulsom; Roy Bicknell

From the Angiogenesis Laboratory (L.-J.A., S.S., J.M.J.H., R.B.), Cancer Research UK, Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford; Cancer Research UK Angiogenesis Group (V.L.H., S.K., J.F.J.B., J.M.J.H., J.A.L., R.B.), The Institute for Biomedical Research, University of Birmingham Medical School, Edgbaston; and Cancer Research UK (R.P.), The London Research Institute, Lincoln’s Inn Fields, London, UK.

Correspondence to Roy Bicknell, Cancer Research UK Angiogenesis Group, The Institute for Biomedical Research, University of Birmingham Medical School, Edgbaston, Birmingham, B15 2TT, United Kingdom. E-mail R.Bicknell{at}bham.ac.uk

Objective— We aimed to characterize the expression and function of a novel transcript that bioinformatics analysis predicted to be endothelial specific, called endothelial-specific molecule-2 (ECSM2).

Methods and Results— A full-length cDNA was isolated and predicted ECSM2 to be a putative 205–amino acid transmembrane protein that bears no homology to any known protein. Quantitative polymerase chain reaction analysis in vitro and in situ hybridization analysis in vivo confirmed ECSM2 expression to be exclusively endothelial, and localization to the plasma membrane was shown. Knockdown of ECSM2 expression in human umbilical vein endothelial cells using siRNA resulted in both reduced chemotaxis and impaired tube formation on matrigel, a solubilized basement membrane, both processes involved in angiogenesis. A yeast 2 hybrid analysis using the ECSM2 intracellular domain identified filamin A as an interacting protein. This interaction was confirmed by precipitation of filamin-A from endothelial cell lysates by a GST-tagged intracellular domain of ECSM2.

Conclusion— This study is the first to characterize a novel cell surface protein ECSM2 that regulates endothelial chemotaxis and tube formation, and interacts with filamin A. These studies implicate a role for ECSM2 in angiogenesis via modulation of the actin cytoskeleton.

Expression of a novel endothelial specific gene called ECSM2 has been characterized in vitro and in vivo. ECSM2 is a transmembrane protein with no homology to known proteins that regulates endothelial tube formation and chemotaxis in vitro, and couples to filamin-A.


Key Words: endothelial genes • transmembrane proteins • filamin • cell signaling • chemotaxis • angiogenesis